Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine

Antiviral Therapy

Volumn 3, Issue 3, 1998, Pages 169-176

  Opravil, Milos ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; ZIDOVUDINE;

EID: 0031771930     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. Journal of the American Medical Association 1997; 277:1962-1969.
2. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP & Rinaldo CR Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997; 126:946-954.
3. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC & Hirsch MS for the AIDS Clinical Trials Group Study 175 Virology Study Team. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New England Journal of Medicine 1996; 335:1091-1098.
4. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS & Kahn J for the AIDS Clinical Trials Group (ACTG) 116B/117 Study Team and the ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. Journal of Infectious Diseases 1996; 174:704-712.
5. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS & Hamilton JD for the VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Annals of Internal Medicine 1997; 126:939-945.
6. Aboulker JP for the Delta Coordinating Committee and Virology Group. HIV-1 RNA quantification in 1280 patients in the Delta trial and relationship to clinical outcome. Antiviral Therapy 1997; 2 (suppl. 5):61 (Abstract 59).
7. Kozal MJ, Kroodsma K, Winters MA, Shafer-RW, Efron B, Katzenstein DA & Merigan TC. Didanosine resistance in HIV infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine 1994; 121:263-268.
8. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S & Crumpacker CS for the AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. Journal of Infectious Diseases 1996; 174:696-703.
9. Johnson VA, Nail CD, Hazelwood JD, Marangos M, Smith R, Thompson M & Koel JL. Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice. Antiviral Therapy 1997; 2 (suppl. 5):72
10. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO & Richman DD for the AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Annals of Internal Medicine 1995; 122:401-408.
11. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JMA, for the INCAS Study Group. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Journal of the American Medical Association 1998; 279:930-937.
12. Markowitz M, Cao Y, Vesanen A, Talal A, Hurley A, Schluger R, Tenner-Racz K, Racz P & Ho DD. Intensive virological assessment of aggressively treated subjects with recent and chronic HIV infection. Antiviral Therapy 1997; 2 (suppl. 5):116 (Abstract 126).
13. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337:734-739.
14. Vandamme AM, Harrer T, Van Laethem K, De Vroey V, Rascu A, Grunke M, Low P, Kalden JR, Desmyter J & De Clercq E. Lack of resistance mutations (including M184V) in treatment-naive HIV-1 seropositives for up to 7 months after initiation of a lamivudine-containing three- or four- drug combination therapy, except for one patient with previous zidovudine resistance. Antiviral Therapy 1997; 2 (suppl. 5):123 (Abstract 137).
15. De Jong JJ, Foudraine N, Ruismans R, Baan E, Van der Schoot A, Lange JMA & De Wolf F. First-line treatment with zidovudine/lamivudine or stavudine/lamivudine rapidly leads to lamivudine resistance even in patients with a serum HIV RNA load below 50,000 copies/ml. Antiviral Therapy 1997; 2 (suppl. 5):67 (Abstract 68).
16. 16; Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C & Wainberg MA. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrobial Agents and Chemotherapy 1993; 37:1390-1392.
17. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ & Emini EA. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.